MedTrace Logo

Epigenetic Regulation of Immunity in Alpha-1 Anti-trypsin Deficiency

NCT02691611 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 39

Last updated 2025-06-06

No results posted yet for this study

Summary

The investigators hypothesize that environmentally influenced histone modifications regulate AM mediated inflammation, contributing to a variable clinical course of AATD, and may also influence or be influenced by the activity of AAT augmentation therapy.

Conditions

Sponsors & Collaborators

  • Medical University of South Carolina

    collaborator OTHER

  • National Jewish Health

    lead OTHER

Principal Investigators

  • Brian P O'Connor, PhD · National Jewish Health

  • Nabeel Y Hamzeh, MD · National Jewish Health

  • Robert Sandhaus, MD, PhD · National Jewish Health

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2018-11-30
Completion
2020-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02691611 on ClinicalTrials.gov